<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font22 { font-size : 22; } .font28 { font-size : 28; } .font29 { font-size : 29; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">fingolimod </span>
   <span class="font29">POMS </span>
   <span class="font28">patients </span>
   <span class="font22">multiple </span>
   <span class="font19">{border-style </span>
   <span class="font19">disease </span>
   <span class="font19">interferon </span>
   <span class="font18">px;} </span>
   <span class="font18">#ffffff;} </span>
   <span class="font17">sclerosis </span>
   <span class="font16">beta-a </span>
   <span class="font16">relapse </span>
   <span class="font16">compared </span>
   <span class="font15">PARADIGMS </span>
   <span class="font15">lesion </span>
   <span class="font15">treatment </span>
   <span class="font15">adverse </span>
   <span class="font14">onset </span>
   <span class="font14">Fingolimod </span>
   <span class="font14">Neurol </span>
   <span class="font14">events </span>
   <span class="font14">pediatric </span>
   <span class="font14">rate </span>
   <span class="font14">reported </span>
   <span class="font14">trial </span>
   <span class="font14">years </span>
   <span class="font13">(.%) </span>
   <span class="font13">POMS. </span>
   <span class="font13">group </span>
   <span class="font13">patient </span>
   <span class="font13">px; </span>
   <span class="font13">risk </span>
   <span class="font13">{font-family </span>
   <span class="font13">AOMS </span>
   <span class="font13">Chitnis </span>
   <span class="font13">MRI </span>
   <span class="font13">Multiple </span>
   <span class="font13">POMS, </span>
   <span class="font13">Pediatric </span>
   <span class="font13">cases </span>
   <span class="font13">clinical </span>
   <span class="font13">font-size </span>
   <span class="font13">gadolinium-enhancing </span>
   <span class="font13">number </span>
   <span class="font13">observational </span>
   <span class="font13">treat </span>
   <span class="font12">Neurology </span>
   <span class="font12">Sclerosis </span>
   <span class="font12">annualized </span>
   <span class="font12">confirmed </span>
   <span class="font12">double; </span>
   <span class="font12">lesions </span>
   <span class="font12">months </span>
   <span class="font12">new </span>
   <span class="font12">prior </span>
   <span class="font12">published </span>
   <span class="font12">sclerosis: </span>
   <span class="font12">Banwell </span>
   <span class="font12">CNS </span>
   <span class="font12">FDA </span>
   <span class="font12">Feng </span>
   <span class="font12">Rensel </span>
   <span class="font12">activity </span>
   <span class="font12">age </span>
   <span class="font12">border-color </span>
   <span class="font12">border-width </span>
   <span class="font12">children </span>
   <span class="font12">disability </span>
   <span class="font12">effects </span>
   <span class="font12">fingolimod. </span>
   <span class="font12">immune </span>
   <span class="font12">report </span>
   <span class="font12">significantly </span>
   <span class="font12">solid; </span>
   <span class="font12">study </span>
   <span class="font12">time </span>
   <span class="font12">treated </span>
   <span class="font12">{font-style </span>
   <span class="font12">{font-weight </span>
   <span class="font11">(fingolimod </span>
   <span class="font11">-month </span>
   <span class="font11">./s--- </span>
   <span class="font11">AOMS. </span>
   <span class="font11">DMT </span>
   <span class="font11">EDSS </span>
   <span class="font11">Huppke </span>
   <span class="font11">Incidence </span>
   <span class="font11">Mult </span>
   <span class="font11">Patients </span>
   <span class="font11">Scler </span>
   <span class="font11">T-weighted </span>
   <span class="font11">approval </span>
   <span class="font11">approved </span>
   <span class="font11">bold </span>
   <span class="font11">case </span>
   <span class="font11">cohort </span>
   <span class="font11">courier; </span>
   <span class="font11">data </span>
   <span class="font11">demonstrated </span>
   <span class="font11">demyelinating </span>
   <span class="font11">discontinuation </span>
   <span class="font11">effect </span>
   <span class="font11">efficacy </span>
   <span class="font11">em; </span>
   <span class="font11">end-points </span>
   <span class="font11">experience </span>
   <span class="font11">experienced </span>
   <span class="font11">factors </span>
   <span class="font11">fingolimod, </span>
   <span class="font11">however, </span>
   <span class="font11">involving </span>
   <span class="font11">lower </span>
   <span class="font11">macular </span>
   <span class="font11">mild </span>
   <span class="font11">patients. </span>
   <span class="font11">pediatric-onset </span>
   <span class="font11">population </span>
   <span class="font11">prescribing </span>
   <span class="font11">pt;} </span>
   <span class="font11">received </span>
   <span class="font11">results </span>
   <span class="font11">sclerosis. </span>
   <span class="font11">scores </span>
   <span class="font11">similar </span>
   <span class="font11">studies </span>
   <span class="font11">therapy </span>
   <span class="font11">tolerability </span>
   <span class="font11">trial, </span>
   <span class="font11">trial. </span>
   <span class="font11">unique </span>
   <span class="font11">vs. </span>
   <span class="font11">work </span>
  </p>
 </body>
</html>
